Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina; Translational Health Research Center (CENITRES), Maimónides University, Buenos Aires, Argentina.
Cell. 2024 Jun 6;187(12):2897-2897.e1. doi: 10.1016/j.cell.2024.05.009.
Resmetirom is an oral selective THR-β agonist conditionally approved for the treatment of patients with noncirrhotic MASH with moderate to advanced fibrosis. Resmetirom restores mitochondrial and hepatic metabolic function; reduces atherogenic lipids; improves hepatic steatosis, inflammation, and fibrosis; and has no significant effect on THR-α. To view this Bench to Bedside, open or download the PDF.
雷美替莫是一种口服选择性 THR-β激动剂，有条件批准用于治疗非肝硬化性 MASH 伴有中度至重度纤维化的患者。雷美替莫可恢复线粒体和肝脏代谢功能；降低动脉粥样硬化脂质；改善肝脂肪变性、炎症和纤维化；对 THR-α 无明显影响。要查看此从实验室到临床，请打开或下载 PDF。
